News
ORI Capital is planning a US$350 million fund to focus on Chinese biotech, with hopes that AI will help beat the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback